Integrative effects of Telomere Length, Epigenetic Age, and Mitochondrial DNA abundance in Alzheimer's Disease

Shea J Andrews[1†], Brendan A Mitchell[2,3], Tong Tong[4,5], Luke W. Bonham[2,6], Alan E Renton[7], Xiaoling Zhang[4,5,8], Marina Sirota[9,10], Duygu Tosun[2], Kristine Yaffe[1,6,11] for the Alzheimer's Disease Neuroimaging Initiative

[1] Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA, USA

[2] Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA

[3] UCSF-UC Berkeley Joint PhD Program in Bioengineering, Berkeley, CA, USA.

[4] Bioinformatics Program, Boston University, Boston, MA, USA

[5] Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

[6] Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA

[7] Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[8] Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

[9] Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA

[10] Department of Pediatrics, University of California, San Francisco, CA, USA

[11] Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

† Corresponding author
Shea Andrews, PhD
Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of California San Francisco
Nancy Friend Pritzker Psychiatry Building
675 18th St
shea.andrews@ucsf.edu

Abstract

Background and Objectives: Biological age, reflecting the cumulative molecular and cellular damage such as telomere attrition, epigenetic alterations and mitochondrial dysfunction, may better capture age-related decline and Alzheimer's disease (AD) risk than chronological age. Most studies have focused on one measure of biological age and not investigated joint or interactive contributions to AD pathogenesis.

Methods: We estimated blood-derived telomere length (TL) via qPCR, epigenetic age (DNAm age) using the CausAge clock, and mitochondrial DNA copy number (mtDNAcn) from whole genome sequencing in 640 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI; Age: 74.91±7.56, Female: 44.8%, Cognitively Unimpaired: 34.3%, Mild Cognitive Impairment: 52%, AD: 12.9%). Linear mixed-effects models examined the associations and interactions of these markers with cognitive decline for memory, executive function, language ability, visuospatial ability, and global cognition, while linear regression tested associations with cross-sectional AD biomarkers (CSF $A\beta_{42}$, total-tau, $pTau_{181}$, and meta-ROI for cortical thickness and gray matter volume). Models adjusted for baseline age, sex, clinical dementia rating scale, *APOE*, blood cell composition, and outcome-specific covariates (education and intracranial volume).

Results: Individually, TL and DNAm age, were not associated with cognition, CSF biomarkers, or neuroimaging outcomes, while higher mtDNAcn was associated with lower CSF tau and $ptau_{181}$. Interaction models revealed that mtDNAcn modified the effects of both TL and DNAm age: at higher mtDNAcn, shorter TL predicted poorer global cognition ($\beta = 0.033 \pm 0.014$, $p = 0.020$) and older DNAm age predicted poorer language performance ($\beta = -0.059 \pm 0.028$, $p = 0.038$). A significant three-way interaction showed that the combination of higher mtDNAcn, longer TL, and older DNAm age was associated with lower grey-matter volume.

Discussion: These findings suggest that increased mtDNAcn may act as a compensatory response to accelerated epigenetic aging and telomere attrition. Our results underscore the importance of evaluating the interplay among multiple biological aging markers when investigating AD pathogenesis.

Glossary: mtDNAcn: mitochondrial DNA copy number; TL: telomere length; AD: Alzheimer's disease; CDR-SB: Clinical dementia rating sum of boxes; CSF: cerebrospinal fluid

Introduction

Age is one of the strongest risk factors for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), with dementia incidence increasing sharply with advancing chronological age [1]. The aging process is driven by the accumulation of molecular and cellular damage, which proceeds at different rates among individuals and defines a person's biological age [2]. The "hallmarks of aging" comprise 12 independent biological processes characterized by such damage, including telomere attrition, epigenetic alterations, and mitochondrial dysfunction, which have been associated with an increased risk of dementia [3]. However, how multiple measures and their interactions among these aging hallmarks collectively influence AD pathogenesis remains poorly understood.

DNA methylation (DNAm) is a heritable yet dynamic epigenetic modification that modulates gene expression, primarily through the addition of methyl groups to the 5-position cytosine residues within CpG dinucleotides [3]. Epigenetic clocks estimate biological age, termed epigenetic age (DNAm age), by quantifying age-associated changes in DNAm patterns at specific CpG sites [4]. Accelerated epigenetic aging (i.e., the difference between DNAm age and chronological age) has been associated with increased dementia risk [5], poorer cognitive performance [5], reduced total brain and hippocampal volume [6,7], and AD neuropathology [8]. Telomeres are nucleoprotein structures capping the ends of chromosomes that are essential for maintaining genomic integrity [9]. Telomeres progressively shorten with successive cell divisions, and shorter telomere length (TL) has been associated with increased AD/ADRD risk, lower cognitive performance, smaller hippocampal volume, and reduced total brain tissue volume [10–13]. Mitochondrial dysfunction is an early and prominent feature of AD characterized by impaired glucose metabolism, dysregulated mitochondrial fusion/fission, elevated oxidative stress, disturbed Ca2+ homeostasis, and altered expression of nuclear-encoded mitochondrial genes and proteins [14]. Mitochondrial DNA copy number (mtDNAcn) – the number of mitochondrial genomes per cell – serves as a biomarker of mitochondrial activity and a proxy for overall mitochondrial function [15,16]. Lower blood-based mtDNAcn at baseline is associated with increased risk of dementia 17 years later [17] and worse cognitive performance [18], while lower brain-derived mtDNAcn was associated with higher odds of AD neuropathology [14,19].

While TL, mtDNAcn, and epigenetic age are individually associated with AD pathogenesis, these hallmarks of aging are mechanistically interconnected. Mitochondria produce reactive oxygen species (ROS) that can induce DNA damage, thereby accelerating telomere shortening [20]. Shortened telomeres can activate the tumor suppressor gene p53, which subsequently inhibits PGC-1α—a master regulator of mitochondrial biogenesis—leading to decreased mitochondrial function, reduced ATP production, and further elevation of ROS levels [21,22]. Furthermore, age-related epigenetic changes can alter the expression of nuclear-encoded mitochondrial genes, impacting mitochondrial function [23]. Conversely, metabolic signals originating from mitochondria can trigger epigenetic modifications within the nuclear genome [24,25]. Accelerated epigenetic aging is associated with telomere attrition [26,27], and individuals with telomere biology disorders often exhibit accelerated epigenetic age,

suggesting premature cellular aging [28]. Thus, a comprehensive understanding of biological aging's impact on AD pathogenesis necessitates evaluating the interplay among these key aging hallmarks.

Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, we investigated whether TL, DNAm age, and mtDNAcn interact to influence AD endophenotypes—cognitive performance, core cerebrospinal-fluid biomarkers, and MRI-based neurodegeneration measures—over and above the independent contribution of each biomarker.

Methods

Alzheimer's Disease Neuroimaging Initiative

Genomic and clinical data were obtained from the ADNI, a longitudinal, observational study launched in 2004 as a public-private partnership, enrolling participants at over 50 sites across the United States and Canada and has been described in detail previously [29].

This study leveraged data from ADNI participants for whom whole-genome sequencing, DNAm profiling, telomere length measurements, cognitive assessments, CSF biomarker acquisition, and magnetic resonance imaging data were available. For the present study, 'baseline' was defined as the time point corresponding to the isolation of DNA from which genomic data were generated. Up to 640 participants with the required genomic and clinical data were included, including 216 cognitively unimpaired older adults (CU), 330 individuals with mild cognitive impairment (MCI), and 94 individuals with a clinical diagnosis of dementia due to AD (Table 1). Clinical symptoms severity was assessed using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score [30].

Standard Protocol Approvals, Registrations, and Patient Consents

The ADNI study was approved by the ethical standard committee at each participating site, and all participants provided written informed consent for imaging and genetic sample collection, and questionnaires, as approved by each site's institutional review board. ADNI investigators contributed to the study design and data collection but were not involved in the analysis or writing of this report.

AD Endophenotypes

Cognitive Performance

Participants undergo an extensive neuropsychological battery at visit including the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Schedule–Cognition (ADAS-Cog), Boston Naming Test, Rey Auditory Verbal Learning Test (RAVLT), Wechsler Memory Scale–Revised (WMS-R) Digit Span, WMS-R Logical Memory, Trails A & B, clock drawing, animal fluency, and the Montreal Cognitive Assessment (MoCA) [29,31]. Using this test battery, the ADSP-PHC has generated harmonized cognitive domain scores [32]. Briefly, a panel of content experts considers every test from each protocol and assigns it to a single primary

cognitive domain – either memory, executive functioning, language, visuospatial ability, or other. Tests administered consistently across cohorts serve as anchor items and facilitate co-calibration. Confirmatory factor analysis is applied to each cognitive domain, choosing between models based on fit statistics and person-level impact, producing co-calibrated scores for memory, executive functioning, language, and visuospatial functioning. We further created a global cognitive domain score by averaging the domain scores.

CSF Amyloid and tau biomarkers

CSF was collected by lumbar puncture and levels of $A\beta_{42}$, total-tau (tau), and phosphorylated tau ($pTau_{181}$) were quantified on the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) and Innogenetics INNO-BIA Alz-Bio3 (Innogenetics, Ghent, Belgium) immunoassay reagents, as described previously [33]. Harmonization of the raw CSF levels was performed by the ADSP-PHC by log-transforming the protein values, removing outliers (defined as values below Q1 − 1.5×IQR or above Q3 + 1.5×IQR, where Q1 and Q3 are the first and third quartiles, respectively), and then z-standardizing the protein values [34]. The current analyses used the closest CSF collection to the baseline genomics measurements; every included CSF measurement was obtained within one year of DNA isolation.

Neuroimaging

The ADSP-PHC conducted pre-processing and quality control of T1 MRI scans via Freesurfer, with longitudinal COMBAT used to harmonize across scanner platforms and models, site, and field strengths [35]. We constructed an AD-Signature composite that combines measures of cortical thickness and gray matter volume across six regions [36]. For gray matter volume, we averaged the right and left volumes for the hippocampus, amygdala, entorhinal, middle temporal, inferior temporal, and temporal pole; and then summed their volumes to create an overall volume measure. For cortical thickness, we averaged the right and left measurements for the entorhinal, fusiform, inferior temporal, middle temporal, inferior parietal, and precuneus regions and estimated the volume-weighted average of the six regional thicknesses to yield the cortical-thickness meta-ROI. The current analyses used the cortical thickness and gray matter volume at last visit – excluding those participants whose last MRI was conducted at the same visit at which genomics were collected.

Biological Aging

Epigenetic Age

DNA methylation (DNAm) profiling was conducted on genomic DNA extracted from whole blood sample using the Illumina Infinium Human MethylationEPIC V1 BeadChip Array, following previously described protocols [37]. Raw DNAm intensity data were normalized using the dasen method implemented within the `wateRmelon` R package [38]. Quality control procedures were applied at both the probe and sample levels using the `minfi` and `DMRcate` R packages [39,40]. CpG probes were excluded if they exhibited a detection p-value > 0.05 across all samples, were located within 5 base pairs of known single-nucleotide polymorphisms annotated with a minor allele frequency >0.01, were identified as cross-hybridizing probes, or were located on sex

chromosomes (X or Y). Samples were excluded if their estimated bisulfite conversion efficiency fell below 85%. After applying these QC filters, 673,027 high-quality probes were retained for downstream analyses.

Epigenetic age was derived using CausAge clock, implemented via the `Biolearn` Python package [4,41]. The CausAge clock is derived from 586 CpG sites previously identified through Mendelian randomization analyses as having potential causal associations with the aging process.

Mitochondrial DNA copy number

Mitochondrial DNA copy number (mtDNAcn) quantification has been described in detail previously [42]. Briefly, whole-genome sequencing CRAM files were processed using Mosdepth to estimate base coverage for both mtDNA and autosomal DNA. mtDNAcn was then calculated as twice the ratio of the mean mtDNA coverage to the mean autosomal coverage, thereby accounting for the diploid nature of the nuclear genome ([mean coverage of mtDNAcn / mean coverage of autosomes] x 2).

Telomere Length

Telomere length estimation and quality control have previously been described in detail [43]. Briefly, genomic DNA was extracted from buffy coats or blood samples. Quantitative polymerase chain reaction (qPCR) was used to determine the relative telomere length as the ratio of telomere repeats to a single-copy gene (T/S ratio). The T/S ratios were adjusted for experimental variables, including plate, row, column, sample type (blood or buffy coat), and the storage time between DNA extraction and qPCR. The adjusted T/S ratios were then converted into base pairs using the formula: telomere base pairs = 3274 + 2413 × (T/S ratio).

Cell type Deconvolution

To account for cellular heterogeneity in blood, relative proportions for the six most abundant cell types found in blood (neutrophils, monocytes, NK cells, B cells, CD4+ T cells, and CD8+ T cells) were estimated from the bulk methylation data, using a reference-based deconvolution approach implemented via the `Biolearn` Python package [41]. CpG sites for deconvolution were determined by identifying the 50 most distinctively hyper- and hypo-methylated sites per cell type (a total of 600 reference CpG sites), prioritized by the significance of their differential methylation.

Statistical Analysis

Differences in demographics, AD endophenotypes (cognitive function, CSF biomarkers, and neurodegeneration), and biological aging measures across diagnosis at study baseline were determined using a Kruskal-Wallis rank sum test, Pearson's Chi-squared test, or Fisher's exact test. Differences in biological aging markers across diagnostic groups were tested using one-way ANOVA with Tukey's HSD post hoc tests.

For each AD endophenotype, we: 1) evaluated the independent effect of each biological aging marker in separate regression models; 2) assessed their joint effect by including all markers in a single regression model;

and 3) examined interactions by evaluating two-way interactions (mtDNAcn × TL; mtDNAcn × CausAge; TL × DNAm age) and a three-way interaction (mtDNAcn × TL × CausAge). Significance was set a priori at $\alpha = 0.05$. All analyses were conducted in R (v4.4.3).

Linear mixed-effects models were used to evaluate the association of TL, CausAge, and mtDNAcn with cognitive decline (global cognition and each cognitive domain) in participants with at least two cognitive visits. Both time (in years from baseline) and the intercept were included as fixed and random effects to assess the association of TL, mtDNAcn, and DNAm age and their interactions with baseline global cognitive function and cognitive decline. Models adjusted for baseline age x time, CDR-SB x time, *APOE* genotype (ε2 carriers [ε2/ε2, ε3/ε3], ε3/ε3, and ε4 carriers [ε2/ ε4, ε3/ε4, ε4/ε4]) x time, sex, education (high school, college, graduate level), and blood cell-type composition (monocytes, NK cells, B cells, CD4+ T cells, and CD8+ T cells; neutrophils were excluded to avoid multicollinearity). Baseline CDR-SB was included as a covariate to adjust for disease stage as it provides a finer gradation of clinical severity than simple clinical diagnosis or CDR global score, particularly in cognitively unimpaired and mild-impairment range [44]. Including baseline chronological age as a covariate allows us to determine whether epigenetic age explains outcome variation independently of, and in addition to, chronological age.

Linear regression models were used to evaluate the cross-sectional associations of TL, mtDNAcn, and CausAge and their interactions with CSF $A\beta_{42}$, tau, and $pTau_{181}$, adjusting for age, sex, CDR-SB, *APOE* genotype, and blood cell-type composition.

Linear regression models assessed the association of each biological aging marker and their interactions with cortical thickness and gray matter volume at the last visit, adjusting for age, sex, CDR-SB, months since baseline, *APOE* genotype, blood cell-type composition, and intracranial volume (for gray matter volume). MRI at last visit was used to strengthen the temporal ordering between exposure and outcome, with baseline biological-age markers measured first, and subsequent cortical-thickness or gray-matter volume reflects the cumulative neurodegenerative change that followed.

Sensitivity analyses were run without adjusting for CDR-SB for all statistical models.

Results

Cohort Description

Biological aging measures for TL, mtDNAcn, and CausAge were available for 640 participants. The mean age of participants was 74.95 ± 7.62 years, with 44.2% female, 96.1% non-Hispanic White, 33.8% cognitively unimpaired, 51.6% diagnosed with MCI, 14.7% with dementia, and with longitudinal cognitive assessments for a duration of an average of 4.8 ± 3.1 years from the study baseline assessment. MRI data were available for 588 participants, while CSF biomarkers were available for 488 participants within one year of DNA isolation. TL did not differ across diagnostic groups. In contrast, significant differences in mtDNAcn and CausAge were

observed; mtDNAcn was significantly lower in dementia participants compared to MCI, while CausAge was significantly higher in CU participants compared to MCI but lower than in dementia participants. AD endophenotypes were significantly worse in MCI and AD participants compared to CU participants. Both mtDNAcn and TL were negatively correlated with chronological age, whereas CausAge was positively correlated. Similarly, mtDNAcn and TL were positively correlated with each other, but both were negatively correlated with CausAge. Furthermore, mtDNAcn and TL were not correlated with AD endophenotypes, while CausAge was negatively correlated with cortical thickness, gray matter volume, and cognitive function (Figure 1).

TL and CausAge are not associated with AD endophenotypes; mtDNAcn is associated with tau pathology

Linear mixed-effects models were used to estimate the independent and joint associations of each biological aging marker with baseline cognitive function and its longitudinal change. No significant associations were observed for global cognitive function nor any specific cognitive domain (Figure 2; Table S1-5). Similarly, linear regression analyses were conducted to assess the cross-sectional associations of each marker, both independently and jointly, with CSF $A\beta_{42}$, tau, and $pTau_{181}$ (Figure 2; Table S6); higher mtDNAcn was associated with elevated total tau and $pTau_{181}$ levels. Finally, linear regression was used to evaluate the association of baseline TL, mtDNAcn, and CausAge with cortical thickness and gray matter volume at the last visit, and no significant associations were observed (Figure 2; Table S7). Results were consistent in sensitivity analyses, not adjusting for CDR-SB.

mtDNAcn moderates the association of TL and CausAge with cognitive performance and gray matter volume

We evaluated the pairwise interactions between each biological aging marker and AD endophenotypes. Significant interactions were observed between mtDNAcn and TL on baseline global cognition, memory, and executive function, such that, among individuals with short telomeres, higher mtDNAcn was associated with lower cognitive function (Figure 3b; Table S1-3). A significant interaction was also observed between mtDNAcn and DNAm age on baseline language ability; for individuals with an older epigenetic age, higher mtDNAcn was associated with worse language ability (Figure 3c; Table S4). A significant three-way interaction was also observed, such that higher mtDNAcn was associated with reduced gray matter volume in the context of older DNAm age and longer TL Figure 3d; Table S7).

Discussion

Markers of biological aging are not isolated indicators of organismal aging but rather interconnected components of complex processes that drive organismal health. Here, we sought to comprehensively evaluate the joint and interactive effects of TL, mtDNAcn, and DNAm age on AD endophenotypes. We observed that TL, and DNAm age were not associated with cognitive decline, CSF $A\beta_{42}$, tau, and $pTau_{181}$, or meta-ROI for cortical thickness and gray matter volume, while higher mtDNAcn was associated with lower tau and $pTau_{181}$. We also

observed significant interactions, with mtDNAcn moderating the effect of TL and DNAm on cognitive function and gray matter volume.

Prior studies that have used ADNI to investigate the association of TL [43,45,46], DNAm age [5,6,47–50], and mtDNAcn [42] on AD endophenotypes have produced mixed results. TL was not associated with baseline MCI/AD, episodic memory performance, CSF Aβ and tau, nor with regional gray matter volume and cortical thickness [43,45]. However, longer telomere length was associated with faster decline in executive function and interacted synergistically with CSF Aβ, CSF tau, and *APOE* ε4 to worsen executive function [45]. In contrast, shorter telomere length was associated with older predicted brain age but not cognitive age [46]. Only one ADNI study has examined mtDNAcn, with higher mtDNAcn being associated with lower CSF $A\beta_{42}$ but not with FDG- or Amyloid-PET, or A/T/N fluid biomarker [42]. Stratified analyses suggested mtDNAcn was associated with FDG-PET and amyloid-PET in controls, with CSF $A\beta_{42}$ in MCI, with CSF NfL in AD, and with amyloid/tau pathology only in women [42]. DNAm age findings vary with the clock and with the definition of age-acceleration (absolute vs relative vs intrinsic). Third-generation clocks such as DunedinPACE are more consistently associated with increased risk of MCI/AD and worse cognitive performance, whereas first- (Horvath and Hannum) and second-generation clocks (PhenoAge, GrimAge) generally show weak or domain-specific effects [5,48]. In contrast, PhenoAge was associated with incident diagnosis and faster rates of global cognitive decline, while GrimAge was predominantly associated with cortical thinning and WMH burden [51]. Few studies have evaluated the association of epigenetic clocks with CSF A/T/N biomarkers [49]. Collectively, heterogeneity in quantifying epigenic age and modelling choices appears to underlie the inconsistent associations observed across studies.

For the majority of AD endophenotypes, we did not identify any associations with biological aging markers; however, we did observe several interactions with mtDNAcn. Significant interaction-only models can arise when the effect of a predictor changes direction or magnitude across levels of the moderator, such that the positive and negative components cancel when averaged, even though the context-specific effects are strong. First, we observed that among participants with shorter telomere length, higher mtDNAcn was associated with lower cognitive function. Similarly, in participants with an older epigenetic age, higher mtDNAcn was associated with worse language ability. Finally, higher mtDNAcn was associated with reduced gray matter volume in participants with longer telomeres and older epigenetic age. A plausible mechanism is a compensatory increase in mtDNA replication that is initiated when telomere attrition activates p53, suppresses PGC-1α (the master driver of mitochondrial biogenesis), and down-regulates TFAM, thereby compromising oxidative phosphorylation [21,22]. Early in this cascade, a transient drop in TFAM-to-mtDNA ratio results in less compact mitochondrial nucleoids, which facilitates additional mtDNA replication and transcription to restore ETC protein levels and ATP output [52]. Consequently, the observed interaction between shorter telomere attrition and increased mtDNAcn may reflect stress-induced compensation to restore mitochondrial function, rather than robust mitochondrial health [53].

Our findings should be interpreted alongside some study limitations. First, the number of ADNI participants with available genomics to estimate TL, DNAm age, and mtDNAcn is limited, resulting in a small sample size and limited power to detect significant effects. Second, our measures of biological aging were derived from DNA extracted from whole blood and not brain tissue. As such, we assume that blood-derived telomere attrition, epigenetic alterations, and mitochondrial dysfunction reflect systemic biological aging [54,55]. As such, we are unable to determine if interactions between biological aging measures in brain tissue may influence AD pathogenesis. Third, we are unable to control for potential exposome risk factors such as socioeconomic status or lifestyle that may also affect rates of biological aging and AD pathogenesis [56]. Finally, participants in ADNI are primarily non-Hispanic White and have a higher education than the general population. As such, our findings require further replication in diverse prospective population-based cohorts. Despite these limitations, this study exhibits multiple strengths, including the breadth of genomic, cognitive, imaging, and fluid biomarker data available, which allowed us to conduct comprehensive analyses of the joint, independent, and interactive effects of TL, DNAm age, and mtDNAcn on AD pathogenesis.

In conclusion, this study examined how three genomic hallmarks of biological aging - telomere length, DNAm age, and mtDNAcn – influence AD pathogenesis. Independently, only mtDNAcn was associated with tau pathology; however, we also found that DNAm age and TL moderated the effect of mtDNAcn on cognitive function and gray matter volume. These findings argue for a systems-level view of brain aging. The classical “primary hallmarks” of aging—genomic instability, epigenetic alteration, and impaired proteostasis—do not harm neurons or glial cells in isolation; rather, they interact, triggering secondary cascades such as mitochondrial dysfunction, disrupted inter-cellular signaling, and chronic inflammation. Future work should therefore model multiple aging pathways simultaneously and test how their convergence accelerates—or, if targeted therapeutically, slows—AD pathogenesis.

Acknowledgments

ADNI

* Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author Contributions

SJA: Design or conceptualization of the study; analysis or interpretation of the data; drafting of the manuscript for intellectual content. BAM: major role in the acquisition of data; revising the manuscript for intellectual content. TT: major role in the acquisition of data; revising the manuscript for intellectual content. LWB: analysis or interpretation of the data; revising the manuscript for intellectual content. AER: Design or conceptualization of the study; revising the manuscript for intellectual content. XZ: major role in the acquisition of data; revising the manuscript for intellectual content. MS: major role in the acquisition of data; revising the manuscript for intellectual content. DT: analysis or interpretation of the data; revising the manuscript for intellectual content. KY: analysis or interpretation of the data; revising the manuscript for intellectual content

Disclosures

The authors report no relevant disclosures.

Funding

SJA receives funding from NIH-NIA (K99/R00 AG070109) and the Alzheimer's Association (ABA 969581). LWB receives funding from NIH-NIBIB T32EB001631 and RSNA R&E Foundation RR24-217. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or RSNA R&E Foundation.

Data availability

Data is available from https://ida.loni.usc.edu/. Code is available at https://github.com/AndrewsLabUCSF/DNAm.

Tables

Table 1: Demographic, clinical, and biomarker characteristics of the study cohort

Variable	N	CU N = 216	MCI N= 330	Dementia N = 94	p-value[†]
Demographics					
Visits*	640	6 (2)	6 (2)	3 (1)	<0.001
Age	640	77 (7)	73 (8)	77 (8)	<0.001
Female	640	108 (50%)	143 (43%)	32 (34%)	0.031
Education	640				0.6
High School		23 (11%)	47 (14%)	15 (16%)	
College		100 (46%)	136 (41%)	39 (41%)	
Graduate		93 (43%)	147 (45%)	40 (43%)	
NHW	640	206 (95%)	318 (96%)	91 (97%)	0.8
Cognition					
CDR-SB	638	0.07 (0.26)	1.61 (1.07)	5.96 (2.74)	<0.001
Global Cognition	640	0.77 (0.34)	0.41 (0.42)	-0.47 (0.59)	<0.001
Memory	640	0.95 (0.52)	0.33 (0.61)	-0.92 (0.60)	<0.001
Executive Function	640	0.72 (0.46)	0.41 (0.57)	-0.56 (0.77)	<0.001
Language	640	0.82 (0.49)	0.44 (0.51)	-0.29 (0.73)	<0.001
Visual Spatial	640	0.59 (0.45)	0.44 (0.53)	-0.12 (0.76)	<0.001
MRI					
Cortical Thickness, mm	588	2.51 (0.14)	2.46 (0.19)	2.21 (0.19)	<0.001
Gray Matter Volume, mm^3	588	28,054 (3,470)	27,279 (4,486)	22,333 (3,803)	<0.001
CSF[‡]					
$A\beta_{42}$	448	0.43 (0.92)	-0.07 (0.95)	-0.59 (0.82)	<0.001
Tau	433	-0.45 (0.83)	-0.09 (1.05)	0.80 (0.81)	<0.001
$pTau_{181}$	448	-0.09 (0.90)	0.25 (1.10)	0.68 (0.87)	<0.001
Biological Aging					
Telomere Length	640	5,354 (417)	5,405 (403)	5,384 (393)	0.2
mtDNAcn	624	161 (35)	169 (52)	152 (29)	0.009
CausAge	640	63.5 (5.7)	61.7 (5.8)	64.6 (7.3)	<0.001

[†]Comparisons across diagnostic groups using Kruskal-Wallis rank sum test, Pearson's Chi-squared test, or Fisher's exact test. *Average number of visits from DNA isolation. [‡] z-normalized pg/mL

Figures



Figure 1: Pairwise correlations between biological aging markers and AD endophenotypes.



Figure 2: Independent and joint association of biological aging markers with AD endophenotypes. ***A) Independent Effects.*** Each bioage marker (DNAm, mtDNAcn, or TL) was entered in a separate model with the covariate set; β therefore reflects its stand-alone association with the outcome. ***B) Joint effects.*** All three markers were entered simultaneously; β estimates indicate the unique contribution of each marker after mutual adjustment. Magenta denotes statistically significant ($p < 0.05$) effects.


A)
mtDNAcnxTL
mtDNAcnxDNAm
DNAmxTL
mtDNAcnxDNAmxTL
Global Cognition
Memory
Executive Function
Language
Visuospatial ability
Baseline Cog.
Global Cognitive Decline
Memory Decline
Executive Function Decline
Language Decline
Visuospatial ability Decline
Longitudinal Cog.
AB42
pTau
Tau
CSF
Cortical Thickness
GM Vol
MRI
-0.2
0.0
0.2
Standardised β (95% CI)
B)
Global Cognition
mtDNAcn
TL
-0.99
0.02
1.04
C)
Language Ability
mtDNAcn
DNAm
-1.06
-0.1
0.85
D
TL = -1
TL = 0
TL = 0.99
GM Vol.
mtDNAcn
DNAm
-1
0.01
1.01

Figure 3: Interactive effects among biological-age markers on AD endophenotypes: ***A) Coefficient plot.*** Standardized regression coefficients (β, circles) with 95 % confidence intervals (bars) for every two-way interaction (mtDNAcn × TL, mtDNAcn × DNAm, DNAm × TL)and for the three-way interaction (mtDNAcn × DNAm × TL) across baseline cognition, longitudinal cognitive decline, CSF biomarkers, and MRI measures. Magenta denotes statistically significant interactions. ***B) mtDNAcn × TL on global cognition.*** Predicted baseline global-cognition z-score versus mtDNAcn, with telomere length held at –1 SD (red, “short”), 0 SD (blue, “average”), or +1 SD (green, “long”). ***C) mtDNAcn × DNAm on language ability.*** Predicted baseline language-ability z-score versus mtDNAcn, with DNAm-age acceleration fixed at –1 SD (red, “younger”), 0 SD (blue), or +1 SD (green, “older”). ***D) Three-way interaction on grey-matter volume.*** Each facet fixes telomere length at –1, 0, or +1 SD (left-to-right). Within each facet, lines depict the mtDNAcn–grey-matter-volume slope at DNAm–1 SD (red), 0 SD (blue), and +1 SD (green).

References

1. Fang M, Hu J, Weiss J, et al. Lifetime risk and projected burden of dementia. Nat Med. Epub 2025.:1–5.

2. Moqri M, Herzog C, Poganik JR, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186:3758–3775.

3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186:243–278.

4. Ying K, Liu H, Tarkhov AE, et al. Causality-enriched epigenetic age uncouples damage and adaptation. Nat Aging. Epub 2024.:1–16.

5. Sugden K, Caspi A, Elliott ML, et al. Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia. Neurology. 2022;99:e1402–e1413.

6. Milicic L, Vacher M, Porter T, et al. Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience. 2022;44:1807–1823.

7. Whitman ET, Ryan CP, Abraham WC, et al. A blood biomarker of the pace of aging is associated with brain structure: replication across three cohorts. Neurobiol Aging. 2024;136:23–33.

8. Grodstein F, Lemos B, Yu L, et al. The association of epigenetic clocks in brain tissue with brain pathologies and common aging phenotypes. Neurobiol Dis. 2021;157:105428.

9. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–1138.

10. Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Meta-analysis of Telomere Length in Alzheimer's Disease. J Gerontol Ser A: Biomed Sci Méd Sci. 2016;71:1069–1073.

11. Liu R, Xiang M, Pilling LC, et al. Mid□life leukocyte telomere length and dementia risk: An observational and mendelian randomization study of 435,046 UK Biobank participants. Aging Cell. 2023;22:e13808.

12. Hackenhaar FS, Josefsson M, Adolfsson AN, et al. Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers. Alzheimer's Res Ther. 2021;13:130.

13. Rodríguez-Fernández B, Gispert JD, Guigo R, Navarro A, Vilor-Tejedor N, Crous-Bou M. Genetically predicted telomere length and its relationship with neurodegenerative diseases and life expectancy. Comput Struct Biotechnology J. 2022;20:4251–4256.

14. Harerimana NV, Paliwal D, Romero C, et al. Mitochondrial genome abundance is associated with Alzheimer's disease neuropathological burden and cognitive function. Alzheimer's Dement. 2022;18.

15. Castellani CA, Longchamps RJ, Sun J, Guallar E, Arking DE. Thinking outside the nucleus: Mitochondrial DNA copy number in health and disease. Mitochondrion. 2020;53:214–223.

16. Guha M, Avadhani NG. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion. 2013;13:577–591.

17. Stocker H, Beyer L, Perna L, et al. Association of plasma biomarkers, p□tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long□term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. Alzheimer's Dementia. Epub 2022.

18. Zhang Y, Liu X, Wiggins KL, et al. Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts. Neurology. Epub 2023.:10.1212/WNL.0000000000207157.

19. Klein H-U, Trumpff C, Yang H-S, et al. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. Mol Neurodegener. 2021;16:75.

20. Liu L, Trimarchi JR, Smith PJS, Keefe DL. Mitochondrial dysfunction leads to telomere attrition and genomic instability. Aging Cell. 2002;1:40–46.

21. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011;470:359–365.

22. Stukken CVD, Nawrot TS, Alfano R, et al. The telomere-mitochondrial axis of aging in newborns. Aging (Albany NY). 2022;14:1627–1650.

23. Morin AL, Win PW, Lin AZ, Castellani CA. Mitochondrial genomic integrity and the nuclear epigenome in health and disease. Front Endocrinol. 2022;13:1059085.

24. Matilainen O, Quirós PM, Auwerx J. Mitochondria and Epigenetics – Crosstalk in Homeostasis and Stress. Trends Cell Biol. 2017;27:453–463.

25. Zhu D, Li X, Tian Y. Mitochondrial-to-nuclear communication in aging: an epigenetic perspective. Trends Biochem Sci. 2022;47:645–659.

26. Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality. Int J Epidemiology. 2016;45:424–432.

27. Vetter VM, Meyer A, Karbasiyan M, Steinhagen-Thiessen E, Hopfenmüller W, Demuth I. Epigenetic Clock and Relative Telomere Length Represent Largely Different Aspects of Aging in the Berlin Aging Study II (BASE-II). J Gerontol: Ser A. 2019;74:27–32.

28. Carlund O, Norberg A, Osterman P, Landfors M, Degerman S, Hultdin M. DNA methylation variations and epigenetic aging in telomere biology disorders. Sci Rep. 2023;13:7955.

29. Weiner MW, Kanoria S, Miller MJ, et al. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimer's Dement. 2025;21:e14321.

30. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412–2412.

31. Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimer's Dementia. 2010;6:202-11.e7.

32. Mukherjee S, Choi S-E, Lee ML, et al. Cognitive Domain Harmonization and Cocalibration in Studies of Older Adults. Neuropsychology. Epub 2022.

33. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413.

34. Timsina J, Ali M, Do A, et al. Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification. Neurobiol Dis. 2024;190:106373.

35. Leung YY, Lee W-P, Kuzma AB, et al. Alzheimer's Disease Sequencing Project Release 4 Whole Genome Sequencing Dataset. medRxiv. Epub 2024.:2024.12.03.24317000.

36. Schwarz CG, Gunter JL, Wiste HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clin. 2016;11:802–812.

37. Vasanthakumar A, Davis JW, Idler K, et al. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clin Epigenetics. 2020;12:84.

38. Pidsley R, Wong CCY, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genom. 2013;14:293.

39. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30:1363–1369.

40. Peters TJ, Buckley MJ, Statham AL, et al. De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin. 2015;8:6.

41. Ying K, Paulson S, Eames A, et al. Biolearn, an open-source library for biomarkers of aging. bioRxiv. Epub 2024.:2023.12.02.569722.

42. Tong T, Zhu C, Farrell JJ, et al. Blood-derived mitochondrial DNA copy number is associated with Alzheimer disease, Alzheimer-related biomarkers and serum metabolites. Alzheimer's Res Ther. 2024;16:234.

43. Nudelman KNH, Lin J, Lane KA, et al. Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort. J Alzheimer's Dis. 2019;71:33–43.

44. O'Bryant SE, Waring SC, Cullum CM, et al. Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores: A Texas Alzheimer's Research Consortium Study. Arch Neurol. 2008;65:1091–1095.

45. Mahoney ER, Dumitrescu L, Seto M, et al. Telomere length associations with cognition depend on Alzheimer's disease biomarkers. Alzheimer's Dement: Transl Res Clin Interv. 2019;5:883–890.

46. Yu J, Kanchi MM, Rawtaer I, et al. Differences between multimodal brain-age and chronological-age are linked to telomere shortening. Neurobiol Aging. 2022;115:60–69.

47. Engvig A, Kalleberg KT, Westlye LT, et al. Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction. GeroScience. Epub 2024.:1–20.

48. Inkster AM, Duarte-Guterman P, Albert AY, et al. Are sex differences in cognitive impairment reflected in epigenetic age acceleration metrics? Neurobiol Aging. 2022;109:192–194.

49. Sato K, Mano T, Suzuki K, et al. Attempt to Predict A/T/N-Based Alzheimer's Disease Cerebrospinal Fluid Biomarkers Using a Peripheral Blood DNA Methylation Clock. J Alzheimer's Dis Rep. 2020;4:287–296.

50. Bonham LW, Sirkis DW, Pang APS, et al. DNA methylation age from peripheral blood predicts progression to Alzheimer's disease, white matter disease burden, and cortical atrophy. npj Dement. 2025;1:7.

51. Bonham L, Sirkis D, Pang A, et al. DNA methylation age from peripheral blood predicts progression to Alzheimer's disease, white matter disease burden, and cortical atrophy. Res Sq. Epub 2024.:rs.3.rs-5273529.

52. Brüser C, Keller-Findeisen J, Jakobs S. The TFAM-to-mtDNA ratio defines inner-cellular nucleoid populations with distinct activity levels. Cell Reports. 2021;37:110000.

53. Weidling IW, Swerdlow RH. Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. Exp Neurol. 2020;330:113321.

54. Demanelis K, Jasmine F, Chen LS, et al. Determinants of telomere length across human tissues. Science. 2020;369:eaaz6876.

55. Grodstein F, Lemos B, Yu L, Iatrou A, Jager PLD, Bennett DA. Characteristics of Epigenetic Clocks Across Blood and Brain Tissue in Older Women and Men. Front Neurosci. 2021;14:555307.

56. Belsky DW, Baccarelli AA. To promote healthy aging, focus on the environment. Nat Aging. Epub 2023.:1–11.